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Abstract
Contemporary approaches to treating autoimmune diseases like Multiple Sclerosis broadly 
modulate the immune system and leave patients susceptible to severe adverse effects. Antigen-
specific immunotherapies (ASIT) offer a unique opportunity to selectively suppress autoreactive 
cell populations, but have suffered from marginal efficacy even when employing traditional 
adjuvants to improve delivery. The development of immunologically active antigen delivery 
vehicles could potentially increase the clinical success of antigen-specific immunotherapies. An 
emulsion of the antioxidant tocopherol delivering an epitope of proteolipid protein autoantigen 
(PLP139–151) yielded significant efficacy in mice with experimental autoimmune 
encephalomyelitis (EAE). In vitro studies indicated tocopherol emulsions reduced oxidative stress 
in antigen presenting cells. Ex vivo analysis revealed that tocopherol emulsions shifted cytokines 
responses in EAE splenocytes. In addition, IgG responses against PLP139–151 were increased in 
mice treated with tocopherol emulsions delivering the antigen suggesting a possible skew in 
immunity. Overall, tocopherol emulsions provide a functional delivery vehicle for ASIT capable of 
ameliorating autoimmunity in a murine model.
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INTRODUCTION
Current therapeutic approaches to autoimmune diseases such as multiple sclerosis (MS) are 
largely relegated to symptom management alone, and the most effective drugs evoke efficacy 
by imposing global immunosuppression [1–3]. This immunosuppression leaves patients 
susceptible to life-threatening side effects such as opportunistic infections and malignancies 
[4–7]. Indeed, there is a clear history of positive correlation between drug effectiveness and 
risk for adverse outcomes in the clinical treatment of MS [6, 8]. Antigen-specific 
immunotherapy (ASIT) has proven itself compelling as a means to more selectively disarm 
autoimmunity without global immunosuppression. Recent trends suggest co-delivery of 
autoantigen with an immunomodulatory drug may target autoreactive cells to overcome the 
conventional efficacy/safety trade-off in autoimmune therapeutics [9–13].
Co-delivering ASIT and an immune modulator requires spatiotemporal restriction of antigen 
and drug to ensure processing in the same immunological context for eliciting potent, 
antigen-specific outcomes [14, 15]. To accomplish this necessity of space-time proximity, 
formulations have historically utilized vehicles from applications such as vaccines, cancer 
immunotherapy, and sustained-release drug delivery [16–20]. While the polymers and 
metals that make up these vehicles are often touted as biocompatible and immunologically 
inert, co-delivery applications for autoimmunity have periodically shown negative outcomes 
for vehicle control groups in measures such as autoantibody titers and clinical disease 
severity [21, 22]. These studies each reported overall promising therapeutic results, perhaps 
by overcoming deleterious vehicle effects on immunity via the immunosuppression imparted 
through the inclusion of drug. Ultimately, works such as these have resulted in a paradigm 
that inclusion of immunosuppressive drugs is required to overcome inherent 
immunogenicity of formulations.
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In recent work, co-delivery of autoantigen and dexamethasone in incomplete Freund’s 
adjuvant was shown to ameliorate experimental autoimmune encephalomyelitis (EAE), a 
murine model of relapsing-remitting multiple sclerosis [23]. Nevertheless, incomplete 
Freund’s adjuvant is substantially toxic in humans and has even been used to induce EAE in 
primates [24], suggesting poor feasibility in terms of practical therapeutic application for 
autoimmune diseases such as MS. It seems an efficacious ASIT to combat autoimmunity 
should utilize components of a co-delivery system optimally tolerable to humans. 
Furthermore, ASIT delivery vehicles that also exhibit desirable immunological function may 
simplify formulation, yielding a more translatable approach to restore immune tolerance.
Tocopherol emulsions (ETPGS) consisting of vitamin E oil and a PEGylated vitamin E 
surfactant (D-α-Tocopherol polyethylene glycol 1000 succinate, TPGS) in an aqueous 
continuous phase have been approved as safe pharmaceutical adjuvants since 2005 [25, 26]. 
The original application for ETPGS was the sustained delivery of paclitaxel as a 
chemotherapeutic agent, but since its emergence, the formulation has been pervasively 
modified and applied in other applications such as intestinal permeation enhancement and 
copolymerization [27, 28]. Because it has already been approved in humans, tolerability is 
known when considering it as a potential vehicle. In addition, the wealth of various ETPGS 
formulations explored in many discrete biomedical applications indicate the physical 
properties of the suspension are highly tunable. For particulate ASIT delivery approaches in 
cancer, autoimmunity, and vaccines, the immunotherapeutic effect is most commonly 
evoked through nonspecific uptake of the formulation by antigen-presenting cells (APCs), 
leading to downstream inflammation or tolerance by processing of antigen in the context of 
immunostimulatory or suppressive compounds [29–31]. Since ETPGS droplet size is 
versatile, suspensions can be created at mean diameters under 500 nm for optimal APC 
uptake [32]. Importantly, ETPGS can be tuned to have a mean diameter still greater than 100 
nm to enable APC interaction to occur while increasing formulation persistence at the site of 
injection [33–35]. The flexibility of ETPGS for ASIT delivery is augmented by the fact 
vitamin E is an effective antioxidant. The propagation of an immune response is driven by a 
cascade of inflammatory events [36, 37]. By staving off inflammation, antioxidant 
compounds can skew immune responses toward tolerance [27, 38].
Herein, we report on the application of ETPGS to deliver autoantigen and ameliorate EAE in 
vivo. Efficacy was determined by comparing disease scores and weights of EAE mice. The 
immune response was characterized by quantifying cytokine responses in splenocytes and 
by shifts in autoantibody responses in blood and in tissues from the central nervous systems 
in mice. Finally, real-time measurement of oxidation in antigen presenting cells was 




PLP139–151 (PLP), the antigenic peptide used, was purchased from Biomatik (Cambridge, 
ON, Canada). For the induction of EAE, incomplete Freund’s adjuvant (IFA) and killed 
Mycobacterium tuberculosis strain H37RA were purchased from Difco (Sparks, MD) as 
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well as pertussis toxin, purchased from List Biological Laboratories (Campbell, CA). 
Murine RAW 264.7 cells (ATCC® TIB71™) along with Dulbecco’s Modified Eagle’s 
Medium (DMEM), phenol red-free DMEM, fetal bovine serum (FBS), and penicillin/
streptomycin antibiotic solution were procured from American Type Culture Collection 
(ATCC, Manassas, VA, USA) and Atlanta Biologicals (Flowery Branch, GA, USA). 
Diethyldithiocarbamate (DDC), 2-methoxyestradiol (2-ME), phorbol 12-myristate 13- 
acetate (PMA), phosphate-buffered saline (PBS), lipopolysaccharide (LPS, from Escherichia 
coli 0111:B4), sodium dodecyl sulfate (SDS), and bovine serum albumin (BSA) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Interferon-γ (IFN-γ) was obtained 
from Calbiochem (Gibbstown, NJ, USA). 4-Amino-5-methylamino-2’,7’-
difluorofluorescein diacetate (DAF-FM DA) and MitoSOX Red were supplied from Life 
Technologies (Carlsbad, CA, USA). For flow cytometry, Alexa Fluor® 488-conjugated anti-
mouse CD3, Alexa Fluor® 647-conjugated anti-mouse CD19, and Pacific Blue™-
conjugated anti-mouse CD11c, and matched isotype controls were purchased from 
Biolegend (San Diego, CA). Goat HRP-conjugated anti-Mouse IgG for ELISAs was also 
purchased from Biolegend (San Diego, CA). Vitamin E and TPGS were received from 
Sigma Aldrich (St. Louis, MO). Other chemicals and reagents used for these studies were 
analytical grade and used as received.
Preparation of ETPGS Emulsions
ETPGS emulsions were prepared by adding TPGS to 1X phosphate-buffered saline (PBS), 
and agitating overnight at 42.5°C. If PLP was required, the peptide was then dissolved in the 
mixture before the aqueous phase was gently pipetted to a tube containing α-tocopherol 
mineral oil. Next, the tube containing α-tocopherol, TPGS and PBS (with or without PLP) 
was sonicated using a Fisher Scientific™ Sonic Dismembrator Model 500 with a 10 second 
on, 2 second off cadence (30% intensity) for 2 minutes, dipping the emulsion mixture in an 
ice bath during off periods to maintain temperature. After sonication, the emulsion was 
poured into a glass scintillation vial for storage, either on ice or at 4°C. For recipe 
development, amounts used of α-tocopherol, TPGS and PBS were systematically varied, 
though final proportions used for the ETPGS emulsions in these studies were 2:1 α-
tocopherol:TPGS ultimately constituting 10% of a 10:90 oil-in-water emulsion.
Characterizing Size and Peptide Release from ETPGS Emulsions
Dynamic light scattering (DLS) was used to size ETPGS emulsions. Six ETPGS emulsions 
were fabricated (three with PLP, three without) and submitted to a NanoBrook Omni DLS to 
measure mean particle diameter and half-width for each formulation.
For imaging via transmission electron microscopy (TEM), 5 μl of ETPGS or ETPGS+PLP 
was placed onto 300 mesh copper grids with ultrathin carbon film. The wet grids were air-
dried for several minutes prior to being examined under TEM. The emulsions were 
examined by bright-field and dark-field transmission electron microscopy (TEM) using an 
FEI Tecnai F20 transmission electron microscope at an electron acceleration voltage of 200 
kV. High resolution images were captured using a standardized, normative electron dose and 
a constant defocus value from the carbon-coated surfaces.
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To characterize peptide release, 4 mL of ETPGS emulsion containing PLP was inserted into 
regenerated cellulose dialysis tubing (6000–8,000 MWCO, 30 μm wall thickness, 
Fisherbrand Dialysis Tubing). This sealed tubing was submerged in 100 mL of PBS within a 
glass vessel and capped to prevent evaporation. Likewise, the same schematic was used for 
PBS containing PLP at the same concentration as a control. Release vessels were kept at 
37°C with gentle shaking by an incubator (79 rpm, Excella E24 Incubator Shaker, New 
Brunswick Scientific). For sample collection, 1 mL was taken from the 100 mL bulk fluid of 
the release vessels and replaced with 1 mL of fresh PBS. Characterization of PLP 
concentration in samples was performed using reverse-phase HPLC (Waters 2796 
Bioseparations Module, Waters Corp) on a C4 analytical column (Waters XBridge Protein 
BEH column, 300 Å, 3.5 μm, 4.6 mm x 150 mm, 10–500 K). Samples were eluted with 
mobile phases A (100% water with 0.05% trifluoroacetic acid (TFA)) and B (100% 
acetonitrile with 0.05% TFA) with a linear gradient of 95% A to 30% A over 20 minutes at a 
constant flow of 1 mL/min. PLP was detected at 280 nm and DEX was detected at 240 nm 
with a dual wavelength absorbance detector (Waters 2487 Dual λ Absorbance Detector, 
Waters Corp). Data was collected and processed using Empower 3 Software (Waters Corp). 
Concentration losses of peptide from sampling and PBS re-addition were accounted for 
when data were analyzed.
Measurement of ETPGS Antioxidant Power
For assessing antioxidant capabilities of ETPGS emulsions, the ferric-ion reducing 
antioxidant power (FRAP) assay was utilized as previously established [39]. Briefly, ETPGS 
with and without PLP was prepared, diluted 1:1000 and titrated at various concentrations in 
duplicate into FRAP reagent containing Fe(III). Fe(III) conversion to Fe(II) was measured 
by reading samples at a wavelength of 593 nm (Spectramax M5, Molecular Devices) over 
various time points.
Acute Antioxidant Effect in a Model APC
The acute effects of ETPGS on reactive nitrogen and oxygen species (RNOS) in RAW 264.7 
cells were measured using a previously established, highly sensitive microfluidic assay [40, 
41]. Briefly, RAW 264.7 macrophages were cultured in 25 cm3 flasks and maintained at a 
density of 5×106 cells/flask. The cells were stimulated with IFN-γ (600 U/mL) and LPS 
(100ng/mL), and incubated for 20 hours. Cells were then treated with 0.1% (v/v) ETPGS 
and incubated for another 60 minutes. Fluorescent probes DAF-FM DA and MitoSOX were 
loaded into cells at concentrations of 10 μM, each to indicate NO and superoxide species, 
respectively. Also included in the loading were superoxide dismutase inhibitors DDC (1 
mM) and 2-ME (10 μM). After loading, cells were harvested, washed and lysed. The lysate 
was injected into a preconditioned PDMS/glass microfluidic device, and Labview software 
was used to collect and analyze data.
Induction of EAE and Therapeutic Study
Female SJL/J mice, 4–5 weeks of age were obtained from Envigo Laboratories and housed 
at the University of Kansas under specified, pathogen-free conditions. Female SJL/J mice 
are a well characterized and established strain known to exhibit a relapsing-remitting pattern 
of MS-like disease when immunized against the PLP139–151 epitope [42–44]. All live-mouse 
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protocols were approved by the University of Kansas Institutional Animal Care and Use 
Committee. For the induction of EAE, mice were subcutaneously administered with 200 μg 
of PLP in a 0.2 mL emulsion of Complete Freund’s Adjuvant (CFA). The CFA mixture was 
comprised of equal volumes of PBS and IFA also containing killed Mycobacterium 
tuberculosis strain H37RA at a final concentration of 4 mg/mL. This immunization was 
given as four, 50 μL injections above the shoulders and the flanks. Additionally, 200 ng of 
pertussis toxin was given intraperitoneally on the same day of immunization (day 0) as well 
as day 2 post-immunization. The data presented are comprised of three independent in vivo 
studies; each group was comprised of 12–15 mice in total. Treatments were administered as 
100 μL subcutaneous injections on days 4, 7 and 10 of the study. For the PLP and ETPGS
+PLP groups, antigen was dosed at 200 nmol. ETPGS and ETPGS+PLP treatments were 
injected within 30 minutes of fabrication. One of the 15 PBS control mice was excluded 
from the study due to starting weight outside of the appropriate range. Two of 15 ETPGS
+PLP mice died within 24 hours of receiving the third treatment injection due to unclear 
circumstances and were excluded from the study as well. Disease progression was assessed 
on a five-point clinical scale including: 0, no clinical evidence of disease; 1, tail weakness or 
limp tail; 2, paraparesis (weakness or incomplete paralysis of one or two hind limbs); 3, 
paraplegia (complete paralysis of two hind limbs); 4, paraplegia with forelimb weakness or 
paralysis; and 5, moribund. Body weight was taken each day as well.
Tissue Harvest and Splenocyte Isolation
Mouse spleens were harvested from EAE mice on day 25 post-immunization as previously 
described [23, 45, 46]. Briefly, the spleens were first passed through a wire mesh using the 
rubber end of a sterile 1 mL syringe plunger and collected in 5 mL of RPMI 1640 media. 
The cellular extracts were centrifuged, and the resulting cell pellet was resuspended in 3.5 
mL of 1X Gey’s lysis solution. The cells were incubated on ice for 3.5 minutes to lyse 
splenic red blood cells. The lysis reaction was stopped with the addition of 10 mL RPMI 
1640 media containing 10% FBS and centrifuged at 1,100 × g for 5 minutes. The remaining 
splenocyte pellets were resuspended in fresh media (RPMI 1640 media containing 10% FBS 
and 1% Penicillin-Streptomycin) and plated in 96-well cell culture plates at a cell density of 
1×106 cells/well in a final volume of 200 μL, and in 12-well cell culture plates at a density 
of 5×106 cells/well and 1 mL volume. Plain media or 25 μM PLP was immediately 
introduced to cells. Stimulated cell cultures were incubated for 96 hours at 37°C in a CO2 
(5%) incubator.
Additionally, serum was taken from mice during sacrifice by accessing the caudal vena cava. 
Spinal cords were harvested, weighed, and homogenized with the Fisher Scientific™ Sonic 
Dismembrator Model 500 in PBS. The amount of PBS added was determined to create 50 
mg homogenized central nervous tissue (hCNS) per 500 μL of PBS stocks. Serum and hCNS 
samples were stored at −20°C.
Measurement of Cytokines
After 96 hours of incubation, splenocytes in a 96-well culture plate were centrifuged, and 
supernatants were collected for cytokine analysis (GM-CSF, IFN- γ, IL-2, IL-21, IL-4, 
IL-10, IL-15, IL-17, IL-23, TNF-α). Marker levels were detected using a U-Plex assay kit 
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according to manufacturer instructions (Meso Scale Discovery). Briefly, each plate was 
coated with 50 μL of multiplex coating solution consisting of linkers and biotinylated 
capture antibodies for each cytokine and incubated on a shaker at 700 rpm for 1 hour at 
room temperature. Following a 3-time wash step with 150 μL PBS containing 0.05% Tween 
20, 25 μL of diluent and 25 μL of sample was added to each well and incubated again for 1 
hour on a shaker at room temperature. Detection antibody was then added at 50 μL/well and 
incubated for 1 hour. Finally, each assay plate was read using the QuickPlex multiplex plate 
reader (Meso Scale Discovery).
Measurement of Cellular Metabolism
Resazurin (7-hydroxy-3H-phenoxazin-3-one 10-oxide) was used to determine cellular 
metabolism. 75 μM resazurin was introduced to splenocyte cultures and incubated for 3 
hours. Metabolic reductive capacity was observed by viewing changes in fluorescence at 
excitation 560, emission 590 (Spectramax M5, Molecular Devices). Background 
fluorescence were taken using RPMI media and subtracted out from splenocyte readings for 
analysis.
Fluorescent Staining and Flow Cytometry
Splenocytes were collected from 12-well plates at 96 hours and stained with fluorescent 
antibodies. 1×106 cells were washed with 1 mL of wash buffer (RPMI 1640 media 
containing 5% FBS) before being centrifuged and resuspended in 50 μL of block buffer 
containing 20 μg/mL TruStain fcX (anti-mouse CD16/32 antibody, Biolegend) in wash 
buffer. Cells were incubated on ice for 30 minutes before adding the fluorescent antibodies 
and isotype controls in 50 μL at 2x the manufacturer recommended concentration for 1 hour. 
For flow cytometry data collection, 30,000 cells per sample were detected using a BD 
FACSFusion cytometer. Data were analyzed using Kaluza Software.
Detection of Anti-PLP IgG
PLP-specific IgG titers were assessed in an ELISA format [47]. 1μg/mL PLP was dissolved 
in an isoelectric (pH 9.5) solution of 50 mM NaHCO3. This coating buffer was seeded on 
Immulon 2HB 96-well plates and incubated overnight at 4°C. Plates were then blocked at 
37°C for 1 hour with 1% (w/v) bovine serum albumin (BSA) plus 0.5% Tween 20 after 
washing unbound component with the same procedure as used in the multiplex assays. 
Serum and hCNS samples were then introduced and serially diluted 1:1 across seven 
concentrations. After another 1 hour incubation (37°C), plates were again washed, and HRP-
conjugated anti-mouse IgG (BioLegend) was added at 0.1 μg per 100 μL and incubated 
again for 1 hour at 37°C. Washing the plates once more, 100 μL of TrueBlue substrate was 
added and plates were covered and shaken at 75 rpm and room temperature for 15 minutes. 
Enzymatic conversion was stopped with 100 μL 2N H2SO4 and the plate was read at 
450/540 nm (Spectramax M5, Molecular Devices). For analyzing titer, linear regions across 
sample titration readings were fitted with linear regressions and extrapolated to their 1X 
concentration for comparison across samples.
Griffin et al. Page 7














Statistical evaluation of data was performed using two-way analysis of variance (ANOVA), 
followed by Tukey and Sidak multiple comparison tests. The criteria for statistical 
significance for all analyses was set at p<0.05. All statistical analyses were performed using 
GraphPad Software (GraphPad Software Inc.).
RESULTS
Characterization of the ETPGS Formulation
To develop ETPGS as a functional co-delivery vehicle, a formulation recipe was empirically 
derived by altering proportions of vitamin E, TPGS, and phosphate-buffered saline. By 
measuring fabricated particle diameters by DLS, outcomes were reconciled against the 
design criteria for an emulsion to contain droplets between 100–500 nm. Ultimately, a stable 
emulsion was obtained with 10% oil in PBS (w/w) and 2:1 E:TPGS (w/w, Fig. 1A,B). The 
selected formulation was evaluated by fabricating three replicate emulsions, both alone and 
when formulated with PLP (Fig. 1B). The ETPGS recipe alone yielded a mean diameter of 
263.2 nm, and with the inclusion of PLP, the emulsion increased in mean size to 303.1 nm. 
Droplet half-width decreased from 52.3 nm to 32.8 nm, suggesting that PLP may be surface 
active. The emulsions were sized again after one month at 4°C storage; negligible changes in 
droplet size were observed (data not shown). To image the association of PLP with ETPGS 
and confirm incorporation of the peptide into the formulation, transmission electron 
microscopy (TEM) was carried out, which suggested PLP accumulation at the oil-water 
interface (Fig. 1C). Peptide incorporation was further confirmed using elemental analysis to 
visualize nitrogen content within the oil phase of ETPGS with PLP, but not ETPGS alone 
(Supp. Fig. 1). A peptide release study was conducted to verify temporal restriction of 
peptide with the ETPGS formulation as well (Supp. Fig. 2)
ETPGS influences oxidative stress in vitro
To assess the antioxidant capacity of ETPGS emulsions, the ferric-ion reducing antioxidant 
power (FRAP) assay was selected as a colorimetric indicator of functionality. ETPGS with 
and without PLP was fabricated and titrated into FRAP reagent. After 10 minutes, a linear 
concentration dependence was recognized for all components (Fig. 2A). Over time, both 
ETPGS and ETPGS+PLP achieved similar reductions in ferric ions (Fig. 2B). Moving from 
these preliminary results in the simple FRAP system, acute antioxidant effects of ETPGS 
were measured in vitro in a model APC line. LPS-stimulated RAW 264.7 macrophages 
showed substantial levels of MitoSOX Red, but cells treated with ETPGS displayed 
markedly suppressed the analyte (Fig. 2C). Notably, while ETPGS treatment resulted in an 
apparent overall decrease of reactive oxygen species, a slight increase of reactive nitrogen 
species was observed. A third, unknown product peak formed likely as the result of a 
reaction between ETPGS and an indicator dye.
ETPGS-facilitated autoantigen delivery delays and suppresses EAE in vivo
Next, ETPGS formulated with autoantigen was tested for efficacy against EAE in vivo. This 
ETPGS+PLP group was evaluated against ETPGS alone, PLP alone, and PBS control 
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groups with treatment administrations occurring on days 4, 7 and 10 post EAE induction. 
Clinical scoring and weight data were collected, and are reflected in Fig. 3A–C and 3D–F, 
respectively. PBS treated control mice exhibited disease onset at 9 days post-induction and 
reached peak severity (in both weight and clinical score) by day 14. Among PLP-treated 
mice, disease severity was largely suppressed as reflected by both scoring and weight, but 
disease onset occurred at a similar time to those in the PBS control group and was seemingly 
prolonged when compared to PBS control mice. ETPGS vehicle treatment alone 
substantially delayed the onset of EAE with clinical scores not occurring until day 13 and 
peak severity evident on day 16 as opposed to day 14 in the PBS control mice. Treatment 
consisting of ETPGS+PLP delayed disease presentation even further with symptoms not 
appearing until day 15 and a peak at day 19. Disease severity was also suppressed, 
evidenced by lower clinical scores and significantly higher weights even at the end of the 25-
day study. In fact, ETPGS+PLP treatment resulted in greater than 50% of mice showing no 
signs of EAE at all (Fig. 4A). Cumulative scores were tallied for each treatment group and 
are presented in Fig. 4B. ETPGS+PLP treatment indeed significantly suppressed the 
accumulation of clinical scores when compared to PBS control and ETPGS alone, but 
significance was not realized between ETPGS+PLP and PLP alone due to high variability in 
PLP treatment efficacy.
Ex vivo splenocyte cytokines and populations in ETPGS+PLP efficacy
On day 25 of the EAE study, all mice were sacrificed and splenocytes were isolated for ex 
vivo analysis. Isolated splenocytes were cultured for 96 hours either with or without a 25 μM 
autoantigen rechallenge. At the end of the incubation, cytokines were assessed by MSD 
multiplex and cell metabolism was measured via resazurin (Fig. 5). Cell populations were 
also probed using flow cytometry (Fig. 6).
Surprisingly, a highly conserved trend was observed across many cytokines included in the 
study. ETPGS+PLP group splenocytes consistently exhibited elevated levels of cytokines 
when compared to PBS control cells, both in terms of tolerogenic and inflammatory 
cytokines. The most robust cytokine responses evoked in ETPGS+PLP splenocytes were in 
IL-21 and IL-10 (Fig. 5D and 5F), where significant elevation was recognized over all other 
groups. Responses in the PLP group were statistically similar to those in PBS. ETPGS group 
splenocytes showed higher levels of IL-2 than those from PBS control mice (Fig. 5C). 
Interestingly, cell metabolism was significantly elevated in splenocytes from the ETPGS and 
ETPGS+PLP treatment groups (Fig. 5K). This observation, combined with the conserved 
cytokine trend, mirrors the delayed disease presentations that were observed in clinical 
measures.
From cell phenotyping metrics, unchallenged splenocyte populations showed some 
significant differences (Fig. 6A–C). Samples from the ETPGS treatment group had slightly 
decreased numbers of T cells (CD3+) compared to the PLP group, and a higher B cell 
(CD19+) count than PBS and PLP splenocytes. However, antigen-challenged cell population 
differences were not present among T, B, or dendritic cells (CD3+, CD19+, and CD11c+, 
respectively). A rhodamine-conjugated PLP was also used to probe cells capable of 
interacting with autoantigen, particularly by surface recognition of PLP-specific B cells (Fig. 
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6D). Again, resting cells displayed significant differences with PLP, ETPGS and ETPGS
+PLP populations showing lower amounts of cells triggering events in the PLP channel. 
Upon antigen rechallenge, all groups showed similar levels of interaction with PLP. In 
previous ASIT studies investigating co-delivery systems, differences in a unique population 
of CD19+CD11c+ “autoimmune-associated B cells” have been observed and have been 
believed to contribute to tolerogenic outcomes. The same population was gated in this study 
(Fig. 6E), but no statistically relevant differences were found. Finally, T-to-B cell ratio was 
assessed for each group (Fig. 6F), and ETPGS was found to show a B cell-skewed 
proportionality compared to other groups in unchallenged populations, but not upon 
rechallenge. ETPGS+PLP trended similarly to the ETPGS group, but was not significantly 
different than PBS or PLP splenocytes.
Autoantibodies are largely restricted to the periphery in mice treated with ETPGS+PLP
To compare evidence of immunity between the periphery and central nervous system, serum 
and hCNS were harvested and probed for anti-PLP IgG by ELISA (Fig. 7). In the serum 
(Fig. 7A) and hCNS (Fig. 7B) alone, no statistically significant differences existed between 
groups, though tissues from the PLP and ETPGS+PLP treated mice exhibited titers that 
trended higher than the PBS and ETPGS alone groups. However, when comparing the ratio 
of serum-to-hCNS anti-PLP titer (Fig. 7C), a stark difference was realized; ETPGS+PLP 
group titer ratios were markedly higher than those in any other group.
DISCUSSION
While autoantigen delivery as immunotherapy has shown tremendous capability to 
ameliorate autoimmunity across numerous disease models, past applications have pointed to 
the necessity for the inclusion of immunomodulatory molecules (i.e. immunosuppressant, 
adjuvant, etc.), such that the co-delivery of antigen and drug together can elicit maximal 
therapeutic effectiveness [21, 22]. Delivery vehicles have been used to restrict these 
components to the same immunological context, but many of these vessels can evoke 
adverse inflammation, or are regarded as inert at best. In this work, we present ETPGS as a 
functional vehicle for autoantigen delivery, potentially dispensing the need for additional 
drugs or adjuvants. By comparing ETPGS+PLP treatment to ETPGS and PLP alone, we 
evaluated this formulation’s capacity to diminish EAE in vivo.
The development of an ETPGS formulation of appropriate size and stability was empirically 
derived by varying recipe components (Fig. 1A). TPGS content highly influenced emulsion 
droplet sizes, and oil-in-water content had a large bearing on stability. Formulations with 
greater than 25% oil were not stable over time or temperature. A 10% oil-in-water, 2:1 
ETPGS recipe created stable emulsions that were in the ~250–300 nm range (Fig 1B) and 
advanced for further study. PLP was found to be compatible for incorporation with ETPGS, 
as evidenced by TEM (Fig. 1C, Supp. Fig. 1) and peptide release (Supp. Fig. 2). ETPGS was 
confirmed to have antioxidant function in vitro by the FRAP assay (Fig. 2A), and the 
inclusion of PLP did not affect its reductive capacity (Fig. 2B). This antioxidant capability 
was further shown to definitively influence reactive nitrogen and oxygen species production 
by macrophages in vitro.
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Moving to an in vivo murine model of multiple sclerosis, a synergistic effect was realized by 
treating EAE mice with ETPGS+PLP. PLP treatment alone led to a suppressed, but 
prolonged disease state (Fig. 3A, D), while ETPGS treatment resulted in a delayed, though 
fully severe presentation of EAE (Fig 3. B, E). Formulation of ETPGS with PLP as a 
treatment ultimately delayed disease even further compared to ETPGS alone, and the 
severity was dampened to a greater extent than in the PLP group, particularly evidenced by 
fewer days of clinical scores and statistical improvement in weight data at the end of the 
study (Fig. 3C, F). These effects were most pronounced in disease incidence, where 
markedly more ETPGS+PLP mice showed no clinical evidence of disease than any other 
group (Fig. 4A).
Undoubtedly, there was therapeutic benefit to delivering PLP with ETPGS as a vehicle, and 
this effect suggested that these vitamin E emulsions are functionally contributive toward 
combating EAE. Despite this clinical success, ex vivo mechanistic measures proved 
somewhat confounding. ETPGS+PLP cytokine data showed robust production of markers 
such as IL-10 (Fig. 5F) and IL-6 (Fig. 5E), which in combination have been shown to be 
productive toward ameliorating EAE [48–50]. The conserved trend of increased ETPGS
+PLP cytokine production of both IFN-γ (Fig. 5B) and TNF-α (Fig. 5J) was perplexing in 
that each of these are known to be inversely correlated with IL-10 and IL-6, respectively [51, 
52]. In this study, these cytokines among all others assessed were all elevated in the ETPGS
+PLP splenocytes (Fig. 5A–J). Furthermore, cell population data were also inconclusive for 
discerning any induction of tolerance as a mechanism for ETPGS+PLP (Fig. 6). Significant 
differences between groups only existed in unchallenged splenocyte populations, and re-
exposure to PLP consistently led to similar levels of T, B and dendritic cells as well as PLP-
recognizing cells (Fig. 6A–D). In a previous study, therapeutic success was achieved when 
delivering PLP and dexamethasone with IFA, and differences in a distinct population of 
CD19+CD11c+ were seen [23]. These differences were believed to be mechanistically 
contributive, though in this work, no population differences in this subtype were observed 
(Fig. 6E).
Though cytokine and phenotype readouts were largely inconclusive, it remains evident that 
ETPGS+PLP treatment enacted therapeutic efficacy, albeit perhaps not through the 
antioxidant mechanism first hypothesized. Extending from the universally elevated cytokine 
trends, it was apparent that ETPGS+PLP group splenocytes may have been more 
metabolically active than those from other groups. This assertion is substantiated by 
resazurin data (Fig. 6K), where cellular metabolism seems to correlate with temporal 
differences in disease presentation and resolution. While PBS and PLP groups began 
showing disease symptoms on the same day, the delays in both ETPGS and ETPGS+PLP 
onsets may translate to incompletely resolved, or “exhausted” splenocytes on day 25 at 
harvest. Since ETPGS+PLP mice got sick at the latest point in the study, it is reasonable to 
consider the splenocytes of this group may have been in a more stimulated state, affecting 
elevated cytokine levels and resazurin readouts.
To reconcile observed delays in disease, we considered diversion of cells to the injection site 
as an explanation. One notable clinical observation of the ETPGS and ETPGS+PLP 
treatments was that they formed a depot at the injection site. The persistence of emulsion in 
Griffin et al. Page 11













the subcutaneous space was intended to draw immunological attention. This attraction of 
immune infiltrates could contribute to a prioritization of ETPGS and consequentially explain 
the slight delay in disease onset for ETPGS mice. Furthermore, the instance of encountering 
autoantigen in the periphery (as with the ETPGS+PLP treated mice) could trigger 
proliferation of PLP-specific cells before reaching the central nervous system (CNS). This 
off-site proliferation, preceding migration to the CNS, could result in therapeutic efficacy 
against the clinical onset of EAE. In fact, glatiramer acetate, one of the most established MS 
treatments, is characterized by injection site inflammation occurring in up to 60% of patients 
receiving it [53, 54]. The swollen nodules observed at the injection site of EAE mice may 
follow a similar mechanism.
Anti-PLP IgG titers were probed in both the periphery (serum) and central compartment 
(hCNS) of the mice from the study (Fig. 7). Natural antibodies are unable to cross the blood 
brain barrier [55], so quantities were measured in both compartments as long-lasting 
evidence of autoimmunity between each location. While no statistical differences were 
definite in serum or hCNS autoantibodies discretely, the ratio of serum-to-hCNS titer 
yielded a distinct separation where ETPGS+PLP treated mice exhibited a markedly higher 
proportion of autoantibodies restricted to the periphery. These findings give credence to the 
possibility that ETPGS+PLP could create a lasting immunological decoy at the injection 
site. It is notable, however, that compartmental antibody titers trended higher compared to 
other groups for ETPGS+PLP as well. This information highlights the possibility that 
immunity could potentially also be shifted from a T helper type-1 (cellular) response to that 
of Th2 (humoral) response, which is known to be beneficial toward ameliorating EAE and 
MS [56, 57]. Future investigation into the subclass of IgG response will be beneficial to 
discern skewed immunity by ETPGS+PLP, as IgG1/IgG2a ratio could provide information 
about the potentially protective nature of an IgG response in addition to its magnitude [58, 
59]. In all, the data collected in this study suggest that both a decoy effect and 
immunomodulation could be potential factors in the efficacy of ETPGS+PLP.
CONCLUSIONS
The development of autoantigen delivery vehicles that also functionally direct the immune 
response would provide substantial benefit to ASIT for autoimmune diseases. In the past, 
conventional vehicles such as Freund’s adjuvant have fallen short of clinical success [14, 
23]. In this work, the ability of tocopherol emulsions to act as functional vehicles for antigen 
delivery was investigated. PLP delivered by ETPGS was efficacious to ameliorate EAE in 
vivo as evidenced by a decrease in disease incidence as well as severity. While trends of 
skewed cytokine responses were not evident in splenocytes from ETPGS+PLP treated mice 
compared to controls, anti-PLP IgG was slightly elevated and significantly relegated to the 
periphery, potentially indicating a therapeutic shift to Th2-mediated immunity and 
restriction of autoimmune effectors from the CNS compartment. Overall, these data indicate 
that ETPGS can act as a functional delivery vehicle, making it a compelling candidate for 
further study. The pharmaceutical development of MF59 as an emulsion-based vaccine 
adjuvant has shown that large-scale manufacturing of pharmaceutical emulsions can be 
feasible in practice [60, 61], but it will be critical to further elucidate the mechanistic 
potential of ETPGS in general, as well as in the context of authentic autoimmune disorders.
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Moving forward, it is pertinent to further study the mechanistic drivers of therapeutic 
success in ETPGS as an antigen-delivery system. Evidence such as acute in vitro inhibition 
of RNOS production by macrophages and robust IL-10 generation in EAE splenocytes 
support an antioxidant mechanism, but cytokine and cell populations should be more 
carefully explored in secondary lymphoid organs, CNS tissues, and at the site of 
administration before drawing firm conclusions. The decoy effect is substantiated by 
delayed disease onsets and the restriction of anti-PLP IgG to the periphery over the CNS, but 
more work is needed to assess the validity of this phenomenon as a mechanism to correct 
autoimmunity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Formulation of a tocopherol-based vehicle for antigen delivery. A.) Emulsion fabrication 
using varied proportions of Vitamin E, TPGS and PBS enabled the construction of a ternary 
phase diagram, where scale denotes percent composition of each component. B.) Favorable 
component proportions were used to fabricate emulsions both with (ETPGS+PLP) and 
without (ETPGS) PLP for sizing via dynamic light scattering (n = 3/group) DLS sizes and 
half-widths are presented in terms of average size ± standard deviation. C.) formulations of 
ETPGS alone (left) and ETPGS+PLP (right) were also imaged with TEM to verify antigen 
incorporation into the emulsion. The lower right scale bar represents 500 nm for both 
formulations.
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In vitro antioxidant power analyses for ETPGS formulations. Ferric ion reducing antioxidant 
power results yielded A.) linear relationships between reduction and sample dilutions 
(reported for t = 10 minutes), and B.) reduction kinetics over time (reported at sample:FRAP 
ratio 0.09). ETPGS alone is represented by green diamonds, ETPGS+PLP is represented by 
blue circles. C.) Acute measurement of reactive nitrogen and oxygen species in stimulated 
RAW 264.7 cells alone (red), and ETPGS-treated cells (green) for three repeat runs, each. 
Superoxide peaks are identified with blue arrows, while reactive nitrogen peaks are denoted 
by orange arrows.
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Clinical disease scores (A-C) and weight changes (D-F) in EAE mice given treatment 
components. Disease score and weight change data for the PBS control treatment are 
compared to those of PLP treatment (A and D, respectively), ETPGS alone treatment (B and 
E), and ETPGS+PLP treatment (C and F). All treatments were administered on days 4, 7 and 
10 post-disease induction. Each group consisted of n = 12–15 mice combined from three 
independent trials (*p < 0.05, **p < 0.01, ***p < 0.001, ****p< 0.0001 as compared to 
PBS). Error bars are reported as standard deviation among samples.
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Clinical scoring data were analyzed by A.) disease onset by group, as determined by 
proportion of mice having exhibited any clinical score by the day of each time point, and B.) 
area under the scoring curve for each treatment group. (n = 12–15 mice/group, *p < 0.05, 
**p < 0.01, ***p < 0.001). Error bars are reported as standard deviation among samples.
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Splenocytes were harvested on day 25 from EAE mice treated in vivo with PBS, PLP, 
ETPGS alone, or ETPGS+PLP. Splenocytes were incubated for 96h with or without a 25 μM 
PLP rechallenge. Supernatant cytokine levels of A.) GM-CSF, B.) IFN-γ, C.) Il-2, D.) Il-21, 
E.) Il-6, F.) Il-10, G.) Il-15, H.) Il-17, I.) Il-23, and J.) TNF-α were determined and K.) cell 
metabolism was measured via resazurin. (n = 5–6 mice/group, *p < 0.05, **p < 0.01, ***p < 
0.001, ****p< 0.0001). Error bars are reported as standard deviation among samples.
Griffin et al. Page 21














Splenocytes were harvested on day 25 from EAE mice treated in vivo with PBS, PLP, 
ETPGS alone, or ETPGS+PLP. Splenocytes were incubated for 96h with or without a 25 μM 
PLP rechallenge. The cells were stained with antibodies for CD3 (Alexa Fluor 488), CD19 
(Alexa Fluor 647), and CD11c (Brilliant Violet 421), as well as a Rhodamine-labeled PLP. 
Stained splenocytes were analyzed by flow cytometry. Cell populations were evaluated for 
A.) T-cells (CD3+), B.) B-cells (CD19+), C.) Dendritic cells (CD11c+), D.) PLP-specific 
cells (PLP+), and E.) Autoimmune-associated B-cells (CD19+CD11c+). Also analyzed was 
F.) ratio of T cells (CD3+) to B cells (CD19+) for each group. (n = 5–6 mice/group, *p < 
0.05, **p < 0.01, ***p < 0.001, ****p< 0.0001). Error bars are reported as standard 
deviation among samples.
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On day 25 of the in vivo study, blood and spinal cords were collected from EAE mice 
treated with PBS, PLP, ETPGS alone, or ETPGS+PLP. Serum was isolated from blood, and 
spinal cords were homogenized and centrifuged to collect hCNS supernatants. Anti-PLP IgG 
titers were detected by ELISA for both A.) serum and B.) hCNS. C.) Ratio of serum to 
hCNS titers for each mouse was also determined. (n = 5–6 mice/group, *p < 0.05, **p < 
0.01, ***p<0.001). Error bars are reported as standard deviation among samples.
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